

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*

Incyte Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

45337C-10-2

(CUSIP Number)

December 31, 1998

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Cusip No. 45337C-10-2

13G

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Four Partners

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

- (a)
(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

New York

5 SOLE VOTING POWER

1,324,600

NUMBER OF

SHARES
BENEFICIALLY
OWNED BY

6

SHARED VOTING POWER

-0-

EACH
REPORTING
PERSON

7

SOLE DISPOSITIVE POWER

1,324,600

WITH

8

SHARED DISPOSITIVE POWER

-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,324,600

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.8%

12 TYPE OF REPORTING PERSON*

PN

 1 NAME OF REPORTING PERSON
 I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Four-Fourteen Partners LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER

100,000

NUMBER OF

SHARES
 BENEFICIALLY
 OWNED BY

6 SHARED VOTING POWER

-0-

EACH
 REPORTING
 PERSON

7 SOLE DISPOSITIVE POWER

100,000

WITH

8 SHARED DISPOSITIVE POWER

-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

100,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
 SHARES*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

0.4%

12 TYPE OF REPORTING PERSON*

OO

Item 1.

(a) Name of Issuer

Incyte Pharmaceuticals, Inc. (the "Issuer")

(b) Address of Issuer's Principal Executive Offices

3174 Porter Drive
Palo Alto, CA 94304

Item 2.

(a) Name of Persons Filing

This Schedule 13G is being filed jointly by Four Partners ("FP"), a New York general partnership, and Four-Fourteen Partners LLC ("4-14P"), a Delaware limited liability company.

The sole partners of FP are Andrew H. Tisch 1991 Trust, for which Andrew H. Tisch is the managing trustee, Daniel R. Tisch 1991 Trust, for which Daniel R. Tisch is the managing trustee, James S. Tisch 1991 Trust, for which James S. Tisch is the managing trustee, and Thomas J. Tisch 1991 Trust, for which Thomas J. Tisch is the managing trustee. Thomas J. Tisch has been appointed the Manager of FP. Andrew H. Tisch, Daniel R. Tisch, James S. Tisch and Thomas J. Tisch are referred to herein as the "Messrs. Tisch."

The members of 4-14P are trusts for the benefit of the offspring of the Messrs. Tisch, partnerships the partners of which are such trusts and partnerships the partners of which are such partnerships. The Messrs. Tisch serve as the trustees of such trusts. Thomas J. Tisch has been appointed the Manager of 4-14P.

(b) Address of Principal Business Office or, if none, Residence

The mailing address of FP and 4-14P is:

c/o Thomas J. Tisch
667 Madison Avenue
New York, NY 10021

(c) Citizenship

FP is a New York general partnership and 4-14P is a Delaware limited liability company.

(d) Title of Class of Securities

Common Stock, \$.001 par value (the "Shares")

(e) CUSIP Number

45337C-10-2

- Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
- (a) Broker or Dealer registered under Section 15 of the Act,
 - (b) Bank as defined in section 3(a)(6) of the Act,
 - (c) Insurance company as defined in section 3(a)(19) of the Act,
 - (d) Investment company registered under section 8 of the Investment Company Act of 1940,
 - (e) Investment Adviser registered under section 203 of the Investment Advisers Act of 1940,
 - (f) An employee benefit plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see (section) 240.13d-1(b)(1)(ii)(F),
 - (g) A parent holding company, in accordance with (section) 240.13d-1(b)(ii)(G) (Note: See Item 7),
 - (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 - (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 - (j) Group, in accordance with (section) 240.13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to (section) 240.13d-1(c), check this box .

Item 4. Ownership

(a) Amount Beneficially Owned

As of the date hereof, FP is the beneficial owner of 1,324,600 Shares and 4-14P is the beneficial owner of 100,000 Shares. Collectively, FP and 4-14P own 1,424,600 Shares.

(b) Percent of Class

FP is the beneficial owner of 4.8% of the outstanding Shares and 4-14P is the beneficial owner of 0.4% of the outstanding Shares. Collectively, FP and 4-14P own 5.2% of the outstanding Shares.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

FP has directly the sole power to vote or to direct the vote of the 1,324,600 Shares owned by it and 4-14P has directly

the sole power to vote or to direct the vote of the 100,000 Shares owned by it.

- (ii) Shared power to vote or to direct the vote

By virtue of their status as managing trustees of the trusts which are the general partners of FP and as trustees of the trusts which are members of 4-14P, partners of the partnerships that are members of 4-14P and partners of the partnerships that are partners of the partnerships that are members of 4-14P, the Messrs. Tisch may be deemed to have indirectly shared power to vote or direct the vote of the 1,324,600 Shares owned by FP and the 100,000 Shares owned by 4-14P.

- (iii) Sole power to dispose or to direct the disposition of

FP has directly the sole power to dispose or direct the disposition of the 1,324,600 Shares owned by it and 4-14P has directly the sole power to dispose or direct the disposition of the 100,000 Shares owned by it

- (iv) Shared power to dispose or to direct the disposition of

By virtue of their status as managing trustees of the trusts which are the general partners of FP and as trustees of the trusts which are members of 4-14P, partners of the partnerships that are members of 4-14P and partners of the partnerships that are partners of the partnerships that are members of 4-14P, the Messrs. Tisch may be deemed to have indirectly shared power to dispose or direct the disposition of the 1,324,600 Shares owned by FP and the 100,000 Shares owned by 4-14P.

Item 5. Ownership of Five Percent or Less of a Class

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 1999

FOUR PARTNERS

By: /s/ Thomas J. Tisch

Thomas J. Tisch
Manager of Four Partners

FOUR-FOURTEEN PARTNERS LLC

By: /s/ Thomas J. Tisch

Thomas J. Tisch
Manager of Four-Fourteen Partners LLC

AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that Amendment No. 1 to the Schedule 13G dated February [], 1999 relating to the Common Stock, \$.001 par value, of Incyte Pharmaceuticals, Inc., as the same may be amended from time to time hereafter, is being filed with the Securities and Exchange Commission on behalf of each of them.

Dated: February [], 1999

FOUR PARTNERS

By: /s/ Thomas J. Tisch

Thomas J. Tisch
Manager of Four Partners

FOUR-FOURTEEN PARTNERS LLC

By: /s/ Thomas J. Tisch

Thomas J. Tisch
Manager of Four-Fourteen Partners LLC